Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population. Issue 1 (June 2016)

• Record Type: Journal Article
• Authors: Vajna, Erika; Alam, Ruhaniyah; So, Tsz-Yin
• Is Part Of: Cardiology and therapy. Volume 5:Issue 1(2016)
• Page Start: 19
• Page End: 41
• Publication Date: 2016-06
• Subjects: Anticoagulants -- Apixaban -- Dabigatran -- Edoxaban -- Pediatrics; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; Heart -- Diseases -- Treatment -- Periodicals; Cardiovascular Diseases -- Periodicals; 616.12005
• DOI: 10.1007/s40119-015-0054-y
• Languages: English
• ISSNs: 2193-8261

Abstract

Abstract Common treatment options for deep vein thrombosis and venous thromboembolism in the pediatric population include unfractionated heparin, low molecular weight heparin, and warfarin. Other alternatives are bivalirudin, argatroban, and fondaparinux. Warfarin is the only approved oral option, but an oral agent without frequent monitoring would be optimal for pediatric patients. Thus, there is an increasing need for new anticoagulation options in this population. None of the current direct oral anticoagulants have FDA-approved indications and dosing in children. The two classes of DOACs and the drugs they are comprised of are factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitor (dabigatran). Off-label usage of these agents is largely based on adult doses. By far, rivaroxaban and dabigatran have the most published data and ongoing trials in pediatric patients compared to edoxaban and apixaban. After evaluating the current literature available on these agents, it is, however, still too early to make any definitive recommendations on their usage in this special population.